Phase I bioavailability study of PA 10040, POZEN's proprietary combination of aspirin (100mg)/omeprazole (40mg), versus a European Union reference listed enteric-coated (EC) aspirin (100mg)

Trial Profile

Phase I bioavailability study of PA 10040, POZEN's proprietary combination of aspirin (100mg)/omeprazole (40mg), versus a European Union reference listed enteric-coated (EC) aspirin (100mg)

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2013

At a glance

  • Drugs Aspirin/omeprazole (Primary) ; Aspirin
  • Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced ulcer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 08 Aug 2013 New trial record
    • 06 Aug 2013 Status changed from not yet recruiting to completed, based on results reported in a POZEN media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top